206 related articles for article (PubMed ID: 1907150)
1. Antihypertensive and haemodynamic properties of the potassium channel activating (-) enantiomer of cromakalim in animal models.
Clapham JC; Hamilton TC; Longman SD; Buckingham RE; Campbell CA; Ilsley GL; Gout B
Arzneimittelforschung; 1991 Apr; 41(4):385-91. PubMed ID: 1907150
[TBL] [Abstract][Full Text] [Related]
2. RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.
Katz LB; Giardino EC; Salata JJ; Moore JB; Falotico R
J Pharmacol Exp Ther; 1993 Nov; 267(2):648-56. PubMed ID: 8246137
[TBL] [Abstract][Full Text] [Related]
3. Y-27152, a long-acting K+ channel opener with less tachycardia: antihypertensive effects in hypertensive rats and dogs in conscious state.
Nakajima T; Shinohara T; Yaoka O; Fukunari A; Shinagawa K; Aoki K; Katoh A; Yamanaka T; Setoguchi M; Tahara T
J Pharmacol Exp Ther; 1992 May; 261(2):730-6. PubMed ID: 1578381
[TBL] [Abstract][Full Text] [Related]
4. Vasorelaxant effects of cromakalim in rats are mediated by glibenclamide-sensitive potassium channels.
Cavero I; Mondot S; Mestre M
J Pharmacol Exp Ther; 1989 Mar; 248(3):1261-8. PubMed ID: 2495353
[TBL] [Abstract][Full Text] [Related]
5. Cromakalim, a potassium channel activator: a comparison of its cardiovascular haemodynamic profile and tissue specificity with those of pinacidil and nicorandil.
Longman SD; Clapham JC; Wilson C; Hamilton TC
J Cardiovasc Pharmacol; 1988; 12(5):535-42. PubMed ID: 2468052
[TBL] [Abstract][Full Text] [Related]
6. Effects of BRL 34915 (cromakalim) on renal hemodynamics and function in anesthetized dogs.
Hayashi K; Matsumura Y; Yoshida Y; Ohyama T; Hisaki K; Suzuki Y; Morimoto S
J Pharmacol Exp Ther; 1990 Mar; 252(3):1240-6. PubMed ID: 2108239
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacology of Ro 31-6930, a new potassium channel opener.
Paciorek PM; Burden DT; Burke YM; Cowlrick IS; Perkins RS; Taylor JC; Waterfall JF
J Cardiovasc Pharmacol; 1990 Feb; 15(2):188-97. PubMed ID: 1689412
[TBL] [Abstract][Full Text] [Related]
8. BRL 34915, a novel antihypertensive agent: comparison of effects on blood pressure and other haemodynamic parameters with those of nifedipine in animal models.
Buckingham RE; Clapham JC; Hamilton TC; Longman SD; Norton J; Poyser RH
J Cardiovasc Pharmacol; 1986; 8(4):798-804. PubMed ID: 2427821
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive effects of the novel potassium channel activator SKP-450 and its major metabolites in rats.
Shin HS; Seo HW; Oh JH; Lee BH
Arzneimittelforschung; 1998 Oct; 48(10):969-78. PubMed ID: 9825113
[TBL] [Abstract][Full Text] [Related]
10. Effects of the K+ channel activators, RP 52891, cromakalim and diazoxide, on the plasma insulin level, plasma renin activity and blood pressure in rats.
Pratz J; Mondot S; Montier F; Cavero I
J Pharmacol Exp Ther; 1991 Jul; 258(1):216-22. PubMed ID: 1906538
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.
Damiano BP; Giardino EC; Haertlein BJ; Stump GL; Mitchell JA; Falotico R
J Cardiovasc Pharmacol; 1994 Feb; 23(2):300-10. PubMed ID: 7511761
[TBL] [Abstract][Full Text] [Related]
12. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide.
Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG
J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic and pharmacological evaluation of the vasodilator and vasoconstrictor effects of endothelin-1 in rats.
Le Monnier de Gouville AC; Mondot S; Lippton H; Hyman A; Cavero I
J Pharmacol Exp Ther; 1990 Jan; 252(1):300-11. PubMed ID: 2405151
[TBL] [Abstract][Full Text] [Related]
14. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular effects of the novel potassium channel opener (3S,4R)-3-hydroxy-2,2-dimethyl-4-(2-oxo- 1-pyrrolidinyl)-6-phenylsulfonylchromane hemihydrate.
Linz W; Klaus E; Albus U; Becker R; Mania D; Englert HC; Schölkens BA
Arzneimittelforschung; 1992 Oct; 42(10):1180-5. PubMed ID: 1472138
[TBL] [Abstract][Full Text] [Related]
16. The haemodynamic profile of cromakalim in the cat.
Clapham JC; Buckingham RE
J Cardiovasc Pharmacol; 1988; 12(5):555-61. PubMed ID: 2468055
[TBL] [Abstract][Full Text] [Related]
17. Increased vasodilator responsiveness to BRL 34915 in spontaneously hypertensive versus normotensive rats: contrast with nifedipine.
Falotico R; Keiser J; Haertlein B; Cheung WM; Tobia A
Proc Soc Exp Biol Med; 1989 Feb; 190(2):179-85. PubMed ID: 2915996
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological studies of N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (MDL-899), a new long-acting antihypertensive vasodilator.
Baldoli E; Bianchi G; Corsico N; Di Francesco GF
Arzneimittelforschung; 1985; 35(5):818-26. PubMed ID: 2862874
[TBL] [Abstract][Full Text] [Related]
19. Long-lasting hypotensive and antihypertensive effects of a new 1,5-benzothiazepine calcium antagonist in hypertensive rats and renal hypertensive dogs.
Narita H; Murata S; Yabana H; Kikkawa K; Sugawara Y; Akimoto Y; Nagao T
Arzneimittelforschung; 1988 Apr; 38(4):515-20. PubMed ID: 3041970
[TBL] [Abstract][Full Text] [Related]
20. Preferential small arteriolar vasodilatation by the potassium channel opener, BRL 38227, in conscious spontaneously hypertensive rats.
Struijker Boudier HA; Messing MW; van Essen H
Eur J Pharmacol; 1992 Jul; 218(1):191-3. PubMed ID: 1397031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
